|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | |
| C07K 16/22 | |||
| A61P 35/00 | |||
| A61K 31/282 |
| (11) | Number of the document | 3197493 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15777810.1 |
| Date of filing the European patent application | 2015-09-25 | |
| (97) | Date of publication of the European application | 2017-08-02 |
| (45) | Date of publication and mention of the grant of the patent | 2021-03-10 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/052247 |
| Date | 2015-09-25 |
| (87) | Number | WO 2016/049470 |
| Date | 2016-03-31 |
| (30) | Number | Date | Country code |
| 201462055203 P | 2014-09-25 | US |
| (72) |
GYURIS, Jeno, US
LERNER, Lorena, US
LIN, Jie, US
|
| (73) |
Aveo Pharmaceuticals Inc.,
1 Broadway 14th Floor, Cambridge, MA 02142,
US
|
| (54) | METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT |
| METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT |